(19)
(11) EP 3 021 873 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.10.2018 Bulletin 2018/43

(45) Mention of the grant of the patent:
05.09.2018 Bulletin 2018/36

(21) Application number: 14826787.5

(22) Date of filing: 17.07.2014
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
(86) International application number:
PCT/US2014/047071
(87) International publication number:
WO 2015/009955 (22.01.2015 Gazette 2015/03)

(54)

COMPOSITION FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASE

ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ENTZÜNDLICHEN GELENKERKRANKUNGEN

COMPOSITION PUR LE TRAITEMENT D'UNE MALADIE INFLAMMATOIRE ARTICULAIRE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.07.2013 US 201361847851 P

(43) Date of publication of application:
25.05.2016 Bulletin 2016/21

(60) Divisional application:
18167083.7 / 3369435

(73) Proprietors:
  • Xalud Therapeutics, Inc.
    Berkeley, CA 94704 (US)
  • The Regents of the University of Colorado, A Body Corporate
    Denver, CO 80203 (US)

(72) Inventors:
  • CHAVEZ, Raymond, A.
    Alameda, California 94501 (US)
  • WATKINS, Linda, R.
    Boulder, Colorado 80304 (US)
  • LANDRY, Robert
    Erie, Colorado 80516 (US)

(74) Representative: Green, Katherine et al
Mewburn Ellis LLP City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2013/103966
US-A1- 2005 203 032
US-A1- 2009 035 256
US-B2- 7 846 428
WO-A2-2006/130580
US-A1- 2006 116 321
US-A1- 2013 172 410
   
  • WHALEN ET AL: "Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, no. 6, 15 March 1999 (1999-03-15), pages 3625-3632, XP002149335, ISSN: 0022-1767
  • DEBORAH J GORTH ET AL: "IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1[beta]-mediated degradation of nucleus pulposus in v", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 4, 3 August 2012 (2012-08-03) , page R179, XP021117544, ISSN: 1478-6354, DOI: 10.1186/AR3932
  • SLOANE ET AL.: 'Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain: Harnessing innate immunity to enhance gene therapy' GENE THERAPY vol. 16, no. 10, 02 July 2009, pages 1210 - 1222, XP055308809
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).